Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Sirolimus for systemic lupus erythematosus – Authors’ reply

We thank Hannah Q Hu and colleagues for their Correspondence. As described in the title and throughout the paper, our study was an open-label trial.1 Consequently, follow-up double-blind placebo-controlled trials are warranted. This need was repeatedly stated in the abstract and discussion, where we also suggested the need to include a more diverse patient population, since the completed study primarily involved white females.